A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Treatment

The goal of this clinical trial is to learn if the combination of cemiplimab and fianlimab can improve outcomes compared to cemiplimab alone in adults with Human Papillomavirus Positive HPV-positive head and neck cancer who have detectable minimal-residual disease after definitive treatment. The main question(s) it aims to answer are: * Does combining cemiplimab with fianlimab provide better results in preventing cancer recurrence than cemiplimab alone? * Is the combination treatment safe and well-tolerated by patients? Researchers will compare the group receiving cemiplimab alone to the grou

Trial Details

NCT ID

NCT07179315

Phase

PHASE2

Sponsor

University of Chicago

Status

RECRUITING

Cancer Type

Head and Neck Cancer

Interventions

cemiplimab+fianlimab
Cemiplimab

Locations (sample)

Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

Patients must have history of histologically confirmed squamous cell carcinoma of the oropharynx.
Must be HPV positive; testing must be compliant with meeting any one or more of the following criteria:
p16 IHC positivity (p16 IHC interpretation to follow guidelines by Jordan and Lingen et al.37).
HPV PCR positivity.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →